Canaccord Genuity Downgrades Neurocrine Bio. (NBIX) to Hold
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $152.72 --0%
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19
Join SI Premium – FREE
Canaccord Genuity analyst Sumant Kulkarni downgraded Neurocrine Bio. (NASDAQ: NBIX) from Buy to Hold with a price target of $108.00 (from $122.00).
For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.
Shares of Neurocrine Bio. closed at $92.69 yesterday.
You May Also Be Interested In
- Deutsche Bank Downgrades Workday (WDAY) to Hold
- Kotak Downgrades LG Electronics India (LGEL:IN) to Reduce (3)
- Baby Bunting Group Ltd (BBN:AU) PT Raised to AUD1.65 at Macquarie
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
